Skip to main content

Table 2 Incidence of TEAEs by primary system organ class (safety population, N = 77)

From: Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study

 

Combined treatment (IND + GLY)

IND alone (IND + placebo)

All

Primary system organ class

N = 77, n (%)

N = 77, n (%)

N = 77, n (%)

Number (%) of patients with at least one AE

5 (6.5)

3 (3.9)

8 (10.4)

Investigations

1 (1.3)

2 (2.6)

3 (3.9)

Respiratory, thoracic & mediastinal disorders

2 (1.3)

1 (1.3)

3 (3.9)

Infections & infestations

1 (1.3)

0

1 (1.3)

Musculoskeletal and connective tissue disorders

1 (1.3)

0

1 (1.3)

  1. TEAEs treatment-emergent adverse events, IND indacaterol, IND + GLY indacaterol and glycopyrronium, N or n number of patients, AE adverse event